Diagnosis and staging of cardiac masses: additional value of CMR with 18F-FDG-PET compared to CMR with CECT

Mikaïl, Nidaa; Maleš, Lada; Hyafil, Fabien; Benali, Khadija; Deschamps, Lydia; Brochet, Éric; Ehmer, Carsten; Driss, Ahmed Ben; Saker, Loukbi; Rossi, Alexia; Alkhoder, Soleiman; Raffoul, Richard; Rouzet, François; Ou, Phalla

doi:10.1007/s00259-022-05709-9

Cited by 4 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the sensitivity of cardiac magnetic resonance imaging is insufficient, and PET just compensates for the sensitivity of cardiac magnetic resonance imaging, while cardiac magnetic resonance imaging also compensates for its poor specificity. Therefore, some studies suggested combining both methods for a more accurate diagnosis of cardiac masses [ 7 ].…”

Section: Discussionmentioning

confidence: 99%

Multiple thrombi mimicking metastases in the right atrium of patients with non-Hodgkin’s lymphoma diagnosed by multimodal cardiac imaging: one case report

Hu,

Yuan,

Mou

2024

J Cardiothorac Surg

View full text Add to dashboard Cite

Background Right-side heart mass can be found incidentally on routine transthoracic echocardiography (TTE). Accurate diagnosis of cardiac mass often requires more than one imaging method. We present a mid-age woman with non-Hodgkin lymphoma who was found to have multiple right atrial masses mimicking metastases on routine TTE, which were finally diagnosed as thrombi by multimodal cardiac imaging. Case presentation A 52-year-old woman was diagnosed with primary mediastinal diffuse large B cell lymphoma (DLBCL) almost six months prior. The TTE revealed multiple masses in the right atrium with normal cardiac function when she was being evaluated for the next chemotherapy. On arrival, she was hemodynamically stable and asymptomatic. Physical examination was no remarkable. Laboratory findings showed leukocytosis of 17,900 cells/mm3, hemoglobin of 7.5 mg/dL, and a normal D-dimer level. The suspicious diagnosis of right atrial metastasis was made by TEE. However, the diagnosis of right atrial thrombi was made by contrast CMR. Finally, the 18 F-FDG PET-CT demonstrated no metabolic activity in the right atrium, which further supported the diagnosis of thrombi. Eventually, the masses were removed by cardiopulmonary bypass thoracotomy because of a high risk of pulmonary embolism. Histopathology confirmed the diagnosis of thrombi. Conclusions This case highlights the importance of multimodality cardiac imaging in the appropriate diagnosis of a RA masses in patient of lymphoma. Diagnosis of RA masses can be made using multimodal cardiac imaging like TTE, TEE and CMR, even PET. Echocardiography is the most commonly used on multimodal imaging in cardiac thrombus. CMR has high specificity in differentiating a tumor from thrombus, while 18 F-FDG PET has good sensitivity to determine the nature of the masses.

show abstract

Section: Discussionmentioning

confidence: 99%

Multiple thrombi mimicking metastases in the right atrium of patients with non-Hodgkin’s lymphoma diagnosed by multimodal cardiac imaging: one case report

Hu,

Yuan,

Mou

2024

J Cardiothorac Surg

View full text Add to dashboard Cite

show abstract

“…However, the sensitivity of cardiac magnetic resonance imaging is insu cient, and PET just compensates for the sensitivity of cardiac magnetic resonance imaging, while cardiac magnetic resonance imaging also compensates for its poor speci city. Therefore, some studies suggest combining two methods for a more accurate diagnosis of cardiac masses [7].…”

Section: Discussionmentioning

confidence: 99%

Multiple Thrombi mimicking metastases in the right atrium of patients with non-Hodgkin's lymphoma diagnosed by multimodal cardiac imaging：one case report

Hu,

Yuan,

Mou

2023

Preprint

View full text Add to dashboard Cite

Background： Right-side heart mass can be found incidentally on routine transthoracic echocardiography (TTE). Accurate diagnosis of cardiac mass often requires more than one imaging method. We present a mid-age woman with non-Hodgkin lymphoma who was found to have multiple right atrial masses mimicking metastases on routine TTE, which were diagnosed as thrombi by multimodal cardiac imaging eventually. The masses were removed by cardiopulmonary bypass thoracotomy because of a high risk of pulmonary embolism. Case presentation: A 52-year-old woman was diagnosed with primary mediastinal diffuse large B cell lymphoma (DLBCL) almost six months prior. The TTE revealed multiple masses in the right atrium with normal cardiac function when she was being evaluated for the next chemotherapy. On arrival, she was hemodynamically stable and asymptomatic. Physical examination was no remarkable. Laboratory findings showed leukocytosis of 17,900 cells/mm3, hemoglobin of 7.5 mg/dL, and a normal D-dimer level. The suspicious diagnosis of right atrial metastasis was made by TEE. However, the diagnosis of right atrial thrombi was made by contrast CMR. Finally, the 18F-FDG PET-CT demonstrated no metabolic activity in the right atrium, which further established the diagnosis of thrombi. Eventually, the masses were removed by cardiopulmonary bypass thoracotomy because of a high risk of pulmonary embolism, and confirmed thrombi by histopathology. Conclusions: This case highlights the importance of multimodality cardiac imaging in the appropriate diagnosis of a RA masses in patient of lymphoma. Diagnosis of RA masses can be made using multimodal cardiac imaging like TTE, TEE and CMR, even PET. Echocardiography is the most commonly used on multimodal imaging in cardiac thrombus. CMR has high specificity in differentiating a tumor from thrombus, and 18F-FDG PET has more sensitivity to determine the nature of the masses.

show abstract

“…Nuclear medicine imaging and particularly multigated acquisition (MUGA) scintigraphy have historically been at the frontline of LV monitoring in oncological patients. 40 , 41 Although challenged by CMR, 42 nuclear cardiology provides critical information for diagnosing, monitoring, and risk-stratifying cancer patients 15 , 16 , 43 – 45 ( Table 2 ). In the following part, we will review how nuclear cardiology can detect cardiac complications in oncological patients and discuss its role alongside echocardiography and CMR.…”

Section: Role Of Imaging For the Early Detection Of Cvd In Cancer Pat...mentioning

confidence: 99%

“…In this article, we briefly summarize the central mechanisms responsible for cancer-treatment-induced cardiotoxicity, review the main established and emergent nuclear cardiology tools useful in cancer settings, and discuss the role of nuclear medicine alongside echocardiography and CMR. Although also beneficial for managing cardiac tumours, 15 , 16 this review will not cover this topic.…”

Section: Introductionmentioning

confidence: 99%

Tales from the future—nuclear cardio-oncology, from prediction to diagnosis and monitoring

Mikaïl

Chequer

Impériale

et al. 2023

European Heart Journal - Cardiovascular Imaging

Self Cite

View full text Add to dashboard Cite

Cancer and cardiovascular disease often share common risk factors, and patients with cardiovascular disease who develop cancer are at high risk of experiencing major adverse cardiac events. Additionally, cancer treatment can induce short- and long-term adverse cardiovascular events. Given the improvement in oncological patients’ prognosis, the burden in this vulnerable population is slowly shifting towards increased cardiovascular mortality. Consequently, the field of cardio-oncology is steadily expanding, prompting the need for new markers to stratify and monitor the cardiovascular risk in oncological patients before, during, and after the completion of treatment. Advanced noninvasive cardiac imaging has raised great interest in the early detection of cardiovascular diseases and cardiotoxicity in oncological patients. Nuclear medicine has long been a pivotal exam to robustly assess and monitor the cardiac function of patients undergoing potentially cardiotoxic chemotherapies. In addition, recent radiotracers have shown great interest in the early detection of cancer treatment-related cardiotoxicity. In this review, we summarize the current and emerging nuclear cardiology tools that can help identify cardiotoxicity and assess the cardiovascular risk in patients undergoing cancer treatments, and discuss the specific role of nuclear cardiology alongside other noninvasive imaging techniques.

show abstract

Diagnosis and staging of cardiac masses: additional value of CMR with 18F-FDG-PET compared to CMR with CECT

Cited by 4 publications

References 22 publications

Multiple thrombi mimicking metastases in the right atrium of patients with non-Hodgkin’s lymphoma diagnosed by multimodal cardiac imaging: one case report

Multiple thrombi mimicking metastases in the right atrium of patients with non-Hodgkin’s lymphoma diagnosed by multimodal cardiac imaging: one case report

Multiple Thrombi mimicking metastases in the right atrium of patients with non-Hodgkin's lymphoma diagnosed by multimodal cardiac imaging：one case report

Tales from the future—nuclear cardio-oncology, from prediction to diagnosis and monitoring

Contact Info

Product

Resources

About